Biotech

All Articles

Despite mixed market, an equity capital revival can be being available in Europe: PitchBook

.While the biotech financial investment scene in Europe has actually decreased relatively following ...

8 months after a $213M fundraise, genetics publisher Volume makes decreases

.After rearing $213 million in 2023-- some of the year's largest personal biotech shots-- Volume Bio...

BioMarin develops officer team along with biotech vets-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable management hirings, shootings and re...

Biopharma Q2 VC reached highest level since '22, while M&ampA slowed

.Venture capital financing in to biopharma rose to $9.2 billion around 215 handle the 2nd fourth of ...

Bicara, Zenas look for IPOs to push late-phase resources toward market

.Bicara Therapeutics and Zenas Biopharma have delivered clean incentive to the IPO market with filin...

Genentech to close cancer immunology study division

.Genentech will certainly close its cancer cells immunology research team, and unit mind as well as ...

Kezar drops strong cyst but to confirm its really worth in phase 1 test

.Kezar Lifestyle Sciences is actually losing its unpromising stage 1 solid lump medication as the bi...

Acelyrin loses izokibep, lays off 3rd of team

.Even with izokibep sustaining its newly found winning touch in the facility, Acelyrin is actually n...

Rivus' period 2 obesity-related cardiac arrest test reaches endpoint

.Rivus Pharmaceuticals has plumped up the potential customers of its own fat-busting, muscle-sparing...

Ovid halts preclinical job, IV course after soticlestat stop working

.Ovid Therapeutics already exposed last month that it was trimming back its own headcount as the bus...